Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 591,135
  • Shares Outstanding, K 26,261
  • Annual Sales, $ 94,090 K
  • Annual Income, $ -31,290 K
  • 60-Month Beta 1.05
  • Price/Sales 6.13
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade CSTL with:

Options Overview Details

View History
  • Implied Volatility 73.70% ( -11.50%)
  • Historical Volatility 106.87%
  • IV Percentile 55%
  • IV Rank 24.59%
  • IV High 143.75% on 06/17/22
  • IV Low 50.86% on 09/17/21
  • Put/Call Vol Ratio 0.40
  • Today's Volume 14
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 711
  • Open Int (30-Day) 332

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.58
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.65
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -70.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.58 +44.48%
on 06/16/22
24.09 -6.56%
on 06/24/22
+1.40 (+6.63%)
since 06/01/22
3-Month
15.58 +44.48%
on 06/16/22
47.27 -52.38%
on 04/04/22
-23.47 (-51.04%)
since 04/01/22
52-Week
15.58 +44.48%
on 06/16/22
78.58 -71.36%
on 09/07/21
-48.69 (-68.38%)
since 07/01/21

Most Recent Stories

More News
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced findings from a study that evaluated uveal melanoma (UM) patients’...

CSTL : 22.51 (+2.55%)
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the clinical value of the Company’s tests...

CSTL : 22.51 (+2.55%)
Castle Biosciences Announces Support for OHSU’s War on Melanoma™

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new collaboration with OHSU’s War on Melanoma™ . The War on...

CSTL : 22.51 (+2.55%)
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a poster presentation on DecisionDx®-Melanoma at the recent 2022 Fall...

CSTL : 22.51 (+2.55%)
Castle Biosciences to Present at the JMP Securities Life Sciences Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank...

CSTL : 22.51 (+2.55%)
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best New Technology...

CSTL : 22.51 (+2.55%)
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company’s DecisionDx®-Melanoma...

CSTL : 22.51 (+2.55%)
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new study data demonstrating the ability of its TissueCypher® Barrett’s...

CSTL : 22.51 (+2.55%)
Illumina Ventures Announces Promotion and Additions to its Investment Team

Illumina Ventures , today announced the promotion of Malek Faham, MD, PhD, to Chief Scientist having previously served as both a Venture Partner and Entrepreneur in Residence (EIR). In addition, Charles...

ADPT : 8.42 (+4.08%)
AFFX : 14.01 (+0.14%)
CSTL : 22.51 (+2.55%)
GRFS : 12.49 (+5.13%)
NTRA : 36.93 (+4.20%)
ILMN : 191.04 (+3.62%)
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

Research to Prevent Blindness (RPB) and Castle Biosciences today announced that they are partnering to increase opportunities for medical students to gain research experiences, specifically in the field...

CSTL : 22.51 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 23.87
2nd Resistance Point 23.30
1st Resistance Point 22.91
Last Price 22.51
1st Support Level 21.95
2nd Support Level 21.38
3rd Support Level 20.99

See More

52-Week High 78.58
Fibonacci 61.8% 54.52
Fibonacci 50% 47.08
Fibonacci 38.2% 39.65
Last Price 22.51
52-Week Low 15.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar